105 related articles for article (PubMed ID: 10235070)
21. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.
Fridrik MA; Greil R; Hausmaninger H; Krieger O; Oppitz P; Stöger M; Klocker J; Neubauer M; Helm W; Pont J; Fazeny B; Hudec M; Simonitsch I; Radaszkiewicz T
Ann Hematol; 1997 Oct; 75(4):135-40. PubMed ID: 9402845
[TBL] [Abstract][Full Text] [Related]
22. CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
Fridrik MA; Hausmaninger H; Linkesch W; Stöger M; Sill H; Neubauer M; Seewann HL; Klocker J; Haidinger R; Schiller L; Pont J; Raudaschl G; Falk M; Radaszkiewicz T
J Clin Oncol; 1996 Jan; 14(1):227-32. PubMed ID: 8558202
[TBL] [Abstract][Full Text] [Related]
23. Results of treatment with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for non-Hodgkin's aggressive lymphoma analyzed according to the International Prognostic Index.
Aydin F; Ulusoy S; Ovali E
J Chemother; 1997 Dec; 9(6):446-51. PubMed ID: 9491847
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
Rossini F; Terruzzi E; Perego D; Miccolis I; Rivolta F; Manca E; Pogliani EM
Cancer; 2004 Jan; 100(2):350-5. PubMed ID: 14716771
[TBL] [Abstract][Full Text] [Related]
25. Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin, etoposide (CEOP-BE) therapy for intermediate- and high-grade non-Hodgkin's lymphomas.
Mugitani A; Tatsumi Y; Tanaka K; Yasui Y; Inoue T
Anticancer Res; 1999; 19(4C):3393-7. PubMed ID: 10629625
[TBL] [Abstract][Full Text] [Related]
26. CEOP/PEB alternating chemotherapy in advanced intermediate and high-grade non-Hodgkin's lymphomas.
Abate G; Tafuto S; Romano A; Gailli E; Corazzelli G
Haematologica; 1992; 77(4):322-5. PubMed ID: 1385277
[TBL] [Abstract][Full Text] [Related]
27. Cyclophosphamide, epirubicin, vincristine, and prednisone (CEOP) in the treatment of advanced stage non-Hodgkin's lymphomas with poor histology.
Comella P; Abate G; Fiore M; Di Finizio G; Zarrilli D
J Chemother; 1989 Jul; 1(4 Suppl):1257-8. PubMed ID: 16312856
[No Abstract] [Full Text] [Related]
28. ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL).
Silingardi V; Federico M; Cavanna L; Avanzini P; Gobbi PG; Lombardo M; Carotenuto M; Frassoldati A; Pieresca C; Vallisa D
Leuk Lymphoma; 1995 Apr; 17(3-4):313-20. PubMed ID: 8580801
[TBL] [Abstract][Full Text] [Related]
29. Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma.
Al-Ismail SA; Whittaker JA; Gough J
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1379-84. PubMed ID: 3315698
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
[TBL] [Abstract][Full Text] [Related]
31. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
[TBL] [Abstract][Full Text] [Related]
32. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
Tsurumi H; Yamada T; Sawada M; Kasahara S; Kanemura N; Kojima Y; Fukuno K; Hara T; Saio M; Takahashi T; Oyama M; Ozawa K; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2004 Feb; 130(2):107-13. PubMed ID: 14648210
[TBL] [Abstract][Full Text] [Related]
33. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
34. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
Shipp MA; Neuberg D; Janicek M; Canellos GP; Shulman LN
J Clin Oncol; 1995 Dec; 13(12):2916-23. PubMed ID: 8523055
[TBL] [Abstract][Full Text] [Related]
35. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma.
Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M
Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759
[TBL] [Abstract][Full Text] [Related]
36. Results of CHOP chemotherapy for diffuse large B-cell lymphoma.
Hallack Neto AE; Pereira J; Beitler B; Chamone DA; Llacer PD; Dulley FL; Macedo MC; Chaoubah A
Braz J Med Biol Res; 2006 Oct; 39(10):1315-22. PubMed ID: 16906323
[TBL] [Abstract][Full Text] [Related]
37. CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.
Cai MC; Cheng S; Wang X; Hu JD; Song YP; Huang YH; Yan ZX; Jiang YJ; Fang XS; Zheng XY; Dong LH; Ji MM; Wang L; Xu PP; Zhao WL
Genome Med; 2020 Apr; 12(1):41. PubMed ID: 32349779
[TBL] [Abstract][Full Text] [Related]
38. Cyclophosphamide, epirubicin, vincristine and prednisone (CEOP) in the treatment of advanced stage non-Hodgkin's lymphomas with poor histology.
Comella P; Abate G; Fiore M; Di Finizio G; Polverino W; Muto P; Zarrilli D
Haematologica; 1988; 73(6):509-12. PubMed ID: 3148514
[No Abstract] [Full Text] [Related]
39. Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma.
Newell M; Goldstein D; Milliken S; Lewis C; Hoy J; Thomson B; Cooper D
Ann Oncol; 1996 Dec; 7(10):1029-36. PubMed ID: 9037361
[TBL] [Abstract][Full Text] [Related]
40. ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomised study in a multicenter cooperative study group (NHLCSG).
Chisesi T; Santini G; Capnist G; Coser P; Contu A; Porcellini A; Rizzoli V; Sertoli M; Rancan L; Salvagno L
Leukemia; 1991; 5 Suppl 1():107-11. PubMed ID: 1716334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
